Edition:
India

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Capital Market

0.61USD
9:32pm IST
Change (% chg)

$0.01 (+1.03%)
Prev Close
$0.60
Open
$0.60
Day's High
$0.64
Day's Low
$0.60
Volume
12,710
Avg. Vol
77,305
52-wk High
$2.24
52-wk Low
$0.49

Latest Key Developments (Source: Significant Developments)

Aptevo Therapeutics Gets Orphan Drug Designation For APVO436 For The Treatment Of Acute Myelogenous Leukemia
Friday, 6 Dec 2019 

Dec 6 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FOR APVO436 FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA.APTEVO THERAPEUTICS - APVO436 IS CURRENTLY BEING EVALUATED IN A PHASE 1/1B CLINICAL TRIAL IN PATIENTS WITH AML AND MYELODYSPLASTIC SYNDROME.  Full Article

Aptevo Therapeutics Says Qtrly Product Sales $9.0 Mln Vs $5.8 Mln
Thursday, 7 Nov 2019 

Nov 7 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS INC - QTRLY PRODUCT SALES $9.0 MILLION VERSUS $5.8 MILLION.APTEVO THERAPEUTICS - CO HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES AS OF SEPT 30, 2019 TOTALING $25.2 MILLION, INCLUDING $7.5 MILLION IN RESTRICTED CASH..  Full Article

Aptevo Therapeutics Posts Q3 Loss Per Share $0.16
Thursday, 7 Nov 2019 

Nov 7 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.16.  Full Article

Aptevo Therapeutics Reports Continued Progress In Apvo210 And Apvo436 Clinical Trials
Friday, 26 Jul 2019 

July 25 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS CONTINUED PROGRESS IN APVO210 AND APVO436 CLINICAL TRIALS.APTEVO THERAPEUTICS INC - RECEIVES APPROVAL TO BEGIN APVO210 MULTIPLE ASCENDING DOSE (MAD) STUDY.APTEVO THERAPEUTICS INC - NO ANTI-DRUG ANTIBODIES OBSERVED IN APVO210 SAD PHASE 1 STUDY BASED ON PATIENT SAMPLES OBTAINED TO DATE.APTEVO THERAPEUTICS INC - APVO436 PHASE 1 CLINICAL STUDY PROGRESSING ON TRACK; APPROVAL RECEIVED TO BEGIN DOSING IN COHORT 4.APTEVO THERAPEUTICS INC - APVO436 PHASE 1 CLINICAL STUDY PROGRESSING ON TRACK; APPROVAL RECEIVED TO BEGIN DOSING IN COHORT 4.APTEVO THERAPEUTICS INC - LOOK FORWARD TO REPORTING RESULTS FROM MAD STUDY IN Q1 OF 2020.APTEVO - PRELIMINARY DATA SUGGEST SINGLE DOSES OF APVO210 APPEAR TO BE SAFE & WELL TOLERATED AT DOSES EQUIVALENT TO IL-10 DOSES.  Full Article

Aptevo Therapeutics Reports Q1 Loss Per Share $0.44
Thursday, 9 May 2019 

May 9 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.44.ON TARGET FOR LAUNCH OF NEW 3,000 IU IXINITY ASSAY MID-2019.APTEVO THERAPEUTICS- ADVANCES ENROLLMENT IN APVO436 & APVO210 PHASE 1 CLINICAL STUDIES; SEES TOP-LINE PRELIMINARY DATA READ-OUTS IN Q3 & Q4 2019.APTEVO HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES AS OF MARCH 31, 2019 TOTALING $44.5 MILLION.  Full Article

Aptevo Announces Stock Purchase Agreement
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS ANNOUNCES UP TO $35 MILLION COMMON STOCK PURCHASE AGREEMENT WITH LINCOLN PARK CAPITAL.APTEVO THERAPEUTICS INC - PROVIDES CAPITAL OF UP TO $35 MILLION TO APTEVO DURING 36-MONTH TERM OF AGREEMENT.APTEVO THERAPEUTICS - BELIEVE COMBINATION OF CASH, IXINITY CASH FLOW & AGREEMENT PROCEEDS POTENTIALLY PROIVDE ACCESS TO CAPITAL THROUGH H2 OF 2020.  Full Article

Aptevo Therapeutics Q3 Loss Per Share $0.56
Thursday, 15 Nov 2018 

Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.56.Q3 EARNINGS PER SHARE VIEW $-0.57 -- THOMSON REUTERS I/B/E/S.DISCONTINUES CLINICAL DEVELOPMENT OF APVO414 AND OTLERTUZUMAB; SHARPENS FOCUS ON NEXT-GENERATION ADAPTIR PIPELINE.IS ALSO PROGRESSING PLANS TO ADVANCE A SECOND CANDIDATE, APVO210, INTO CLINIC IN Q1 OF 2019.ADVANCES BISPECIFICS APVO436 AND APVO210; ON TRACK TO COMMENCE PATIENT DOSING Q4 2018 AND Q1 2019.HAD CASH, CASH EQUIVALENTS, RESTRICTED CASH, AND SHORT-TERM INVESTMENTS AS OF SEPTEMBER 30, 2018 TOTALING $45.5 MILLION.  Full Article

Aptevo Therapeutics Q1 Loss Per Share $0.63
Thursday, 10 May 2018 

Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.63.QUARTERLY TOTAL REVENUES $4.1 MILLION VERSUS $2.1 MILLION.  Full Article

Aptevo Therapeutics Reports 2017 Financial Results And Provides Business Update
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.APTEVO - ‍HAD CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 TOTALING $91.2 MILLION​.  Full Article